October is Liver Cancer Awareness Month
Join with the AACR to find better ways to prevent and treat liver cancer
Primary liver cancer occurs in adults in two forms—hepatocellular carcinoma and cholangiocarcinoma (bile duct cancer). Hepatocellular carcinoma is the most common type of adult primary liver cancer. It is relatively rare in the United States. However, the incidence of liver cancer is rising, principally in relation to the spread of hepatitis C virus infection.
The liver is one of the largest organs in the body. It filters harmful substances from the blood, produces bile that helps in the digestion of fats, and stores sugar that the body uses for energy.
The National Cancer Institute estimates that 41,630 new cases of liver cancer and intrahepatic bile duct cancer will occur in the United States in 2024. Approximately 29,840 people are expected to die from these cancers. The five-year relative survival rate is 21.7%.
Having hepatitis B, hepatitis C, or cirrhosis are significant risk factors for adult primary liver cancer. It is more common in men than women. In the United States, liver cancer is also more common among Asian Americans/Pacific Islanders and American Indians/Alaska Natives than among other population groups.
One person’s story
Anibal Torres of Humacao, Puerto Rico, was struggling with liver cancer when he enrolled in an immunotherapy clinical trial. His tumor has shrunk, and he says, “The treatment is working. Look at me. I’m living proof.” Read his story in the AACR Cancer Disparities Progress Report 2024.
More on liver cancer
- Patients with liver cancer who received immune checkpoint inhibitors (ICIs) before surgery had similar outcomes to patients who received surgery upfront, according to results from a retrospective study published in the AACR journal Cancer Research Communications. This includes those who would not have been eligible for surgery by conventional criteria.
- Adding stereotactic body radiation therapy (SBRT) to chemotherapy improves overall survival and slows cancer progression in patients with advanced liver cancer, according to a recent clinical trial. Read more in Cancer Today magazine: Radiation for Advanced Liver Cancer.
- A study found that patients who received atezolizumab and bevacizumab after surgery for liver cancer had a lower risk of disease recurrence. Read more in Cancer Today magazine: Post-surgery Option for Liver Cancer.
- On Believe In Progress: An AACR Foundation Podcast, Andrea Wilson Woods describes how the loss of her sister to cancer motivated her to start Blue Faery: The Adrienne Wilson Liver Cancer Organization to help patients and families navigate liver cancer.
How the AACR supports Liver Cancer Research
- Tegwinde Rebeca Compaore, PhD, Institut de Recherche en Sciences de la Santé in Burkina-Faso, received an AACR Beginning Investigator Grant for Catalytic Research (BIG Cat). This supports her study of “Genomics-derived hepatocellular carcinoma risk biomarkers in Africa.”
- Daniel Arango, PhD, Northwestern University, received an AACR Career Development Award to Further Diversity, Equity, and Inclusion in Cancer Research. His study is “Delineating the oncogenic mechanisms of NAT10 in hepatocellular carcinoma.”
For more information
Please see our page on liver cancer for more information on this disease and its prevention, screening, and treatment.
Your gift helps the American Association for Cancer Research fund pioneering science that is saving lives every day.
Donate Now
There are many ways in which you can lend your talents to support lifesaving research. Learn how you can become an advocate for cancer research, participate in events to raise awareness, volunteer your time, and share your story of how cancer has affected your life.
Get Involved